Plain-language reference
A careful vocabulary for people researching Ibo Mind: what names a plant, what names an alkaloid, what names a metabolite, and which safety terms should never be softened by marketing language.
This independent resource distinguishes evidence, safety, legality, and practical questions. It does not offer treatment or medical advice.
Start with the distinction
The primary difference is simple but consequential: iboga is commonly used for the plant Tabernanthe iboga; ibogaine is one psychoactive alkaloid associated with it.
Tabernanthe iboga is an Apocynaceae family rainforest shrub indigenous to Central Africa, primarily Gabon, Cameroon, and the Republic of the Congo. In conversation, iboga can refer to the shrub, its root bark, or a cultural and religious resource.
Ibogaine is a specific indole alkaloid. A concise medical dictionary entry for ibogaine does not make it equivalent to raw plant material, a ceremony, or an approved treatment.
For a practical overview of settings and questions people may encounter, comparative treatment-center research can help clarify why stated screening, monitoring, and follow-up matter more than broad labels.
Plant chemistry
Raw iboga root bark generally contains between 1% and 6% total indole alkaloids by dry weight, with ibogaine constituting roughly half of that alkaloid fraction. Geography, plant age, genetics, plant part, and processing all affect the material.
A total alkaloid extract means a preparation intended to retain a mixture of alkaloids from iboga root bark. It is not the same thing as ibogaine hydrochloride, ibogaine HCl, or a quantified single-compound preparation. Calling every total alkaloid extract “ibogaine” erases that difference.
Secondary alkaloids found in Tabernanthe iboga root bark include tabernanthine, ibogaline, ibogamine, and coronaridine. Those alkaloids have distinct affinity profiles, so a total alkaloid extract cannot be presumed to act like purified ibogaine.
Voacanga africana seeds and bark provide voacangine, an alkaloid precursor commonly used to produce semi-synthetic ibogaine hydrochloride for research and clinical applications. This is why Voacanga africana, voacangine, semi-synthetic ibogaine, and ibogaine HCl often appear together in technical descriptions.
For a fuller plant-versus-compound comparison, this discussion of the difference between iboga and ibogaine is useful context; a broader reference entry on the ibogaine compound also reflects its place in scientific terminology.
Culture and context
In the Bwiti spiritual tradition of Gabon, iboga root bark is treated as an entheogenic sacrament used in community healing rituals and intensive rites of passage. Bwiti practices, meanings, initiation structures, and community norms vary; reducing Bwiti to generic retreat language is culturally misleading.
The term nganga denotes a traditional spiritual healer, herbalist, and ceremonial leader who administers iboga and directs the initiate through the visionary journey. A nganga is not a generic synonym for any retreat facilitator, clinician, or guide.
Gabonese cultural law declared Tabernanthe iboga a national strategic reserve and protected heritage species under a presidential decree issued in 2000. That history makes origin, harvest, commercialization, and benefit-sharing part of the terminology—not side notes.
For people researching Ibo Mind, terms such as entheogen, Bwiti, Central Africa, Gabon, and rite of passage describe context rather than a medical indication. The consumer health overview of iboga is also a reminder that plant terminology does not remove risk.
An entheogen is a substance used within a spiritual or religious framework. The word does not prove safety, efficacy, legality, or suitability for any individual.
Psychonautics refers to intentional exploration of altered states. It is a cultural term, not a substitute for medical supervision or a diagnosis-based care plan.
Integration describes reflection and practical processing after an intense experience. It is not interchangeable with psychotherapy, detoxification, or aftercare.
This phrase should be avoided. Observed changes in opioid withdrawal or craving do not establish sustained remission, and addiction interruption is not a guarantee of recovery.
Pharmacology
Ibogaine is commonly described as an atypical psychedelic and oneirogen. Oneirogenic means dream-producing: the word points to dreamlike, waking-REM visual states rather than classical serotonergic hallucinations. It does not describe a guaranteed therapeutic outcome.
Its pharmacology involves more than one target. Discussions may refer to the NMDA receptor, kappa opioid receptor, mu opioid receptor, serotonin transporter, and other systems. A single receptor phrase cannot explain the full experience, the risks, or the meaning a person assigns to it.
“Oneirogenic” describes a type of subjective state. It is not a synonym for safe, healing, or clinically proven.
The liver enzyme CYP2D6 metabolizes ibogaine through first-pass hepatic conversion into noribogaine. CYP2D6 is part of the cytochrome P450 system, and variation in metabolism is one reason a dose label alone cannot describe exposure or safety.
Ibogaine and noribogaine have been associated in preclinical discussion with expression of glial cell line-derived neurotrophic factor, or GDNF, and brain-derived neurotrophic factor, or BDNF, in the ventral tegmental area. BDNF, GDNF, and neuroplasticity are research terms, not proof that a person’s brain has been reset.
A peer-reviewed account of ibogaine’s matrix pharmacology illustrates why single-target explanations are incomplete. The National Center for Biotechnology Information overview of cytochrome P450 provides useful context for why metabolic pathways matter.
Metabolism and duration
Noribogaine is a major active metabolite of ibogaine. The term active metabolite means that a compound formed by metabolism can itself have biological activity. Noribogaine has a different pharmacokinetic profile and may contribute substantially to prolonged effects.
Half-life describes the time it takes for a concentration to fall by half under defined conditions. A longer half-life can matter for continued effects, drug interactions, and cardiac safety; it does not establish a durable benefit or an uncomplicated recovery.
In discussions of substance use disorder, people may hear claims about addiction interruption, detoxification, opioid withdrawal, withdrawal symptoms, or a reset. These terms should be kept separate. A reduction in opioid withdrawal is not the same as detoxification, remission, or aftercare.
Evidence has been strong enough to support controlled research, but not casual treatment claims. A scientific review available through the PubMed Central literature is useful for placing mechanistic interest alongside uncertainty and risk.
Noribogaine is an active metabolite, not a simple extension of ibogaine. Its pharmacology, half-life, dose-response questions, and cardiotoxicity considerations require their own attention.
Neuroplasticity refers broadly to the capacity of nervous systems to change. It is often invoked alongside BDNF and GDNF, but it should not be converted into a promise of recovery.
Ibogaine-assisted psychotherapy implies a structured psychotherapeutic model before, during, and after dosing. Informal conversation or integration coaching does not automatically meet that definition.
Aftercare is the practical support and planning that follow an intervention. It is distinct from the acute experience and remains important where substance use disorder or opioid withdrawal is involved.
Experience vocabulary
A flood dose refers to an acute therapeutic quantity of ibogaine, historically ranging between 10 to 20 milligrams per kilogram of body weight, intended to interrupt chemical dependence. It is a descriptive protocol term, not an endorsement or a universally safe dosage instruction.
A test dose refers to a smaller preliminary amount used in some protocols. A booster dose is an additional amount sometimes discussed after an initial administration. Microdosing refers to very small quantities, but microdosing does not automatically remove contraindications, QTc prolongation, or interaction concerns.
The acute phase of an ibogaine experience typically lasts from 4 to 8 hours and is characterized by intense internal visions, auditory buzzing, nausea, and pronounced motor ataxia. Ataxia means impaired coordination; it is one reason the acute phase requires careful physical safety planning.
The oneiric phase and oneirogenic effects are often used for internally focused, dreamlike imagery. A later cognitive phase can involve interpretation, memory review, and fatigue. Such descriptions are experiential vocabulary, not evidence that an experience has delivered psychotherapy.
The acute phase is the period of immediate drug effect. It may include nausea, ataxia, limited mobility, and intense oneirogenic phenomena.
The oneiric phase refers to dreamlike imagery or inner narrative. It is related to oneirogenic language but should not be marketed as a predictable rite of passage.
The subsequent reflective phase, colloquially called the gray day, lasts from 12 to 24 hours and can entail emotional processing, cognitive evaluation, and severe physical exhaustion.
Integration can include reflection, psychotherapy, practical support, and aftercare. Its purpose is not to convert an intense event into proof of a cure.
Cardiac safety
Ibogaine and noribogaine can potently block human Ether-a-go-go-Related Gene, or hERG potassium channel, slowing cardiac repolarization and causing concentration-dependent QTc prolongation. hERG potassium channel effects are central to cardiotoxicity discussions.
QTc prolongation means the corrected QT interval on an electrocardiogram is longer than expected. A corrected QT interval exceeding 500 milliseconds creates an elevated clinical risk for torsades de pointes, a potentially fatal ventricular arrhythmia. Torsades de pointes is not a theoretical footnote.
Comprehensive safety protocols require a baseline 12-lead electrocardiogram, complete hepatic panels, and serum electrolyte optimization for potassium and magnesium prior to administration. ECG and electrocardiogram are often used interchangeably; an ECG is not merely paperwork when cardiac risk is involved.
Other critical terms include contraindications, medication interactions, potassium levels, magnesium, electrolyte panel, medical supervision, emergency capability, and monitoring. Prior cardiac disease, liver concerns, active withdrawal symptoms, and concurrent substances can materially change the risk picture.
The FDA’s drug development framework helps explain why investigation is not approval. It is also useful to compare claims about regulation with this overview of ibogaine regulation worldwide.
Legality and claims
In the United States, ibogaine is a Schedule I controlled substance. Schedule I and controlled substance are legal terms describing federal classification. They do not by themselves settle cultural meaning, scientific interest, or a person’s health needs.
Ibogaine is not FDA-approved for treating opioid use disorder, alcohol use disorder, PTSD, depression, or any other condition. That absence of approval is important when promotional language uses “therapy,” “detoxification,” “addiction interruption,” or “psychedelic medicine” without describing evidence limits.
Semi-synthetic ibogaine, ibogaine HCl, ibogaine hydrochloride, raw root bark, and total alkaloid extract may be discussed in the same commercial space, but they are not interchangeable products. Legal status and regulatory classifications can differ across jurisdictions and contexts.
The U.S. Drug Enforcement Administration’s scheduling explanation gives the formal federal context. A separate overview of different iboga and ibogaine forms shows why naming the preparation precisely is practical, not pedantic.
About this resource
Ibomind is an independent information resource for people researching Ibo Mind. Our principles and scope explain why cultural context, safety language, legality, and evidence boundaries are kept visible together.
If you are comparing what public-facing resources mean by screening, preparation, integration, and aftercare, the site’s practical guidance topics are designed to help you identify the questions that should be answered clearly.
A glossary can be helpful when terms accumulate quickly; this example terminology glossary may show the range of language in circulation, while not replacing source-specific definitions or medical assessment.
Claims that ibogaine is used for concussion recovery require particular caution. The discussion of ibogaine and concussions should not be read as evidence of an approved neurological treatment.
Quiet answers
Definitions can clarify a subject without making it simple. The questions below keep plant chemistry, subjective effects, cardiac risk, and clinical language in their separate lanes.
Iboga refers to Tabernanthe iboga, its root bark, and the cultural context in which it may be used. Ibogaine is one alkaloid associated with that plant. A total alkaloid extract contains multiple alkaloids; ibogaine hydrochloride is a named chemical form of one compound.
Total alkaloid extract describes a mixture obtained from plant material rather than purified ibogaine. Because iboga root bark contains ibogaine, tabernanthine, ibogaline, coronaridine, and other alkaloids in variable proportions, it should not be assumed equivalent to ibogaine HCl.
Oneirogenic means dreamlike or dream-producing. With ibogaine, it commonly describes the oneiric phase of waking, internally focused imagery. It is distinct from a claim that psychedelic medicine has produced psychotherapy, neuroplasticity, or a lasting reset.
Noribogaine is an active metabolite formed as CYP2D6 processes ibogaine. Its half-life and activity may contribute to prolonged effects, including changes people describe around opioid withdrawal. That possibility does not establish addiction interruption as a cure for substance use disorder.
Recognize ECG, electrocardiogram, QTc prolongation, hERG potassium channel, torsades de pointes, electrolyte panel, potassium levels, magnesium, contraindications, cardiotoxicity, and medical supervision. These terms belong in any serious discussion of ibogaine therapy, flood dose, or booster dose.
Keep the language precise